Life Science Investing Avidity Biosciences Announces U.S. Managed Access Program for Investigational Therapy del-zota in DMD44
Life Science Investing Avidity Biosciences Reports Third Quarter 2025 Financial Results and Recent Highlights
Life Science Investing Avidity Biosciences Announces Positive Pre-BLA Meeting with U.S. FDA for del-zota in DMD44 with a Submission Planned for Q1 2026
55 North Mining Inc. Announces Completion of Third and Final Tranche of Private Placement for a Total of $4,202,000
